CABOZANTINIB IS EFFECTIVE IN A SUBSET OF XENOGRAFT GBM TUMORS AND AFFECTS MULTIPLE SIGNALING PATHWAYS.

MLA

Mikkelsen, Tom, et al. “Cabozantinib Is Effective in a Subset of Xenograft Gbm Tumors and Affects Multiple Signaling Pathways.” Neuro-Oncology, vol. 16, no. suppl_3, July 2014, p. iii38. EBSCOhost, https://doi.org/10.1093/neuonc/nou208.58.

APA

Mikkelsen, T., deCarvalho, A. C., Arnold, K., Mueller, C., Petricoin, E. F., Poisson, L. M., Irtenkauf, S., & Hasselbach, L. (2014). Cabozantinib Is Effective in a Subset of Xenograft Gbm Tumors and Affects Multiple Signaling Pathways. Neuro-Oncology, 16(suppl_3), iii38. https://doi.org/10.1093/neuonc/nou208.58

Chicago

Mikkelsen, Tom, Ana C. deCarvalho, Kimberly Arnold, Claudius Mueller, Emanuel F Petricoin, Laila M. Poisson, Susan Irtenkauf, and Laura Hasselbach. 2014. “Cabozantinib Is Effective in a Subset of Xenograft Gbm Tumors and Affects Multiple Signaling Pathways.” Neuro-Oncology 16 (suppl_3): iii38. doi:10.1093/neuonc/nou208.58.